Karyopharm Therapeutics (KPTI) FCF Margin (2012 - 2025)
Karyopharm Therapeutics (KPTI) reported FCF Margin of 34.71% for Q4 2025, up 4963.0% on a YoY basis from 0.69% in Q4 2024, and down 160.86% quarter-over-quarter from 13.3% in Q3 2025.
Karyopharm Therapeutics (KPTI) FCF Margin (2012 - 2025) Analysis & Trends
Karyopharm Therapeutics has reported FCF Margin for 14 years, with the latest figure at 34.71% in Q4 2025.
- For the quarter ending Q4 2025, FCF Margin rose 4963.0% year-over-year to 34.71%; the trailing twelve-month figure through Dec 2025 stood at 51.6% (up 3628.0% YoY), and the FY2025 full-year result was 51.6%, up 3628.0% from the prior year.
- FCF Margin for Q4 2025 stood at 34.71%, down from 13.3% in the prior quarter.
- The five-year high for FCF Margin was 20.01% in Q4 2021, with the low at 246.66% in Q2 2021.
- Historically, FCF Margin has averaged 86.38% across 5 years, with a median of 79.27% in 2022.
- Annual changes were most pronounced in 2021 — FCF Margin slumped 12643 bps — and 2022, when it surged 15809 bps.
- Karyopharm Therapeutics' FCF Margin stood at 20.01% in 2021, then sank by 499 bps to 79.94% in 2022, then soared by 31 bps to 55.07% in 2023, then tumbled by 53 bps to 84.33% in 2024, then jumped by 59 bps to 34.71% in 2025.
- The last three FCF Margin figures came in at 34.71% (Q4 2025), 13.3% (Q3 2025), and 49.29% (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | -3.98% |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 43.35% |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | - |
| 10 | Karyopharm Therapeutics | 95.31 Mn | 31.56 Mn | 32.74 Mn | -34.71% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -34.71% |
| Sep 30, 2025 | -13.30% |
| Jun 30, 2025 | -49.29% |
| Mar 31, 2025 | -129.88% |
| Dec 31, 2024 | -84.33% |
| Sep 30, 2024 | -50.16% |
| Jun 30, 2024 | -89.98% |
| Mar 31, 2024 | -132.58% |
| Dec 31, 2023 | -55.07% |
| Sep 30, 2023 | -82.01% |
| Jun 30, 2023 | -68.38% |
| Mar 31, 2023 | -48.87% |
| Dec 31, 2022 | -79.94% |
| Sep 30, 2022 | -78.60% |
| Jun 30, 2022 | -88.57% |
| Mar 31, 2022 | -124.35% |
| Dec 31, 2021 | 20.01% |
| Sep 30, 2021 | -63.57% |
| Jun 30, 2021 | -246.66% |
| Mar 31, 2021 | -227.38% |